Immunovant (IMVT) Earnings Analysis

Immunovant (IMVT) next reports earnings on 2026-08-10, consensus EPS -0.66 USD. Last quarter (2026-05-20) it missed with EPS -0.73 USD vs -0.59202 USD est (-23.3%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -14.05.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does IMVT next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.66 USD
Revenue estimaten/a

IMVT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-20-0.73 USD-0.59202 USD-23.3%Miss
2026-02-06-0.61 USD-0.72 USD+15.3%Beat
2025-11-10-0.73 USD-0.72 USD-1.4%Miss
2025-08-11-0.6 USD-0.69 USD+13%Beat
2025-05-29-0.64 USD-0.71326 USD+10.3%Beat
2025-02-06-0.76 USD-0.73 USD-4.1%Miss

Beat rate: 3/6 (50%) over reported quarters with consensus data.

IMVT valuation and analyst view

Trailing P/E-14.05
Trailing EPS-2.482 USD
Price / book9.33
Dividend yield0.00%
Market cap8.04B
Analyst consensusBuy (18 buy / 4 hold / 1 sell)
Avg price target40 USD

Related research pages

Frequently asked questions

When is Immunovant (IMVT)'s next earnings date?

Immunovant is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.66 USD.

Did IMVT beat earnings last quarter?

In its 2026-05-20 report, IMVT posted EPS of -0.73 USD versus a -0.59202 USD estimate — a miss of 23.3%.

What is IMVT's earnings track record?

Over the last 6 reported quarters with consensus data, IMVT beat estimates 3 times (50%).

What is IMVT's current P/E ratio and EPS?

IMVT trades at a trailing P/E of -14.05 on trailing EPS of -2.4819973872574903 USD.

What do analysts rate IMVT?

Analyst consensus is "Buy" across 23 ratings (0 strong buy, 18 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 40 USD.